Directory · US
Biotechnology Research in United States
A register of firms and the professionals working at them in the Biotechnology Research sector based in United States. Browse the public index, then filter or export on Kipplo.
Companies
12K on file
Concertai
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an Initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services.
1001 to 5000 staff
Cook Myosite
Cook MyoSite is on a mission to make regenerative medicine a part of everyday medicine. As an industry leader in muscle cell technology, we’re establishing new paradigms for muscle-related disorders. Established in 2002, Cook MyoSite was created to guide the Cook Group organization into the expanding world of cellular technologies. We’re proud to be a part of the vibrant medical community in Pittsburgh, Pennsylvania.
51 to 200 staff
Crispr Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc, and R&D operations based in Boston, Massachusetts and San Francisco, California.
201 to 500 staff
Cryo-Cell
Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. In addition to its family bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the U.S in prominent hospitals such as Cedars–Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-Cell’s mission is to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, raise awareness of the opportunity for expectant parents to bank or donate their baby’s cord blood and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA-registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB-accredited as a cord blood facility, Cryo-Cell was also the first U.S.(for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 13485:2003–certified by TÜV, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB:CCEL. For more information, please visit
51 to 200 staff
Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
501 to 1000 staff
Cytovale
Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale
51 to 200 staff
Cytovance Biologics
Streamline your biomanufacturing programs with Cytovance Biologics! Born from a decades-long history in drug development, we believe in creating a healthier world where every biologic’s path to commercialization is advanced by a CDMO partner that delivers ingenuity end-to-end. Whether your large molecule product needs the flexibility of a customized approach or the efficiency of a predetermined platform process, Team Cytovance has the deep expertise in microbial and mammalian expression systems to support your scale-up at every stage. From early needs like cell line development and strain selection to cGMP manufacturing for clinical and commercial production, our team is your team. Together, we will guide your asset through the complexities of manufacturing and deliver it to its next milestone. With a >97% batch success rate and quality, scalability, and reproducibility top of mind, we bring a range of therapeutic proteins and antibodies to the clinic, including: Biosimilars Cytokines Enzymes/Hormones Fusion Proteins Bispecific, Fragment, and Monoclonal Antibodies Recombinant Protein Vaccines And More
201 to 500 staff
Dendreon
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, California. Notice of Fraudulent Activity for Job Applicants Please be aware of the potential for scams from individuals, organizations and internet sites that claim to represent Dendreon Pharmaceuticals in recruitment activities. We strongly recommend that you verify all communications you receive about positions at Dendreon. Any communications from Dendreon would come from an email address that ends in “@dendreon.com”. Dendreon will never ask candidates to provide any type of payment, bank details, photocopies of identification, social security number or other highly sensitive personal information during the recruitment or offer process. Dendreon conducts a formal recruitment process for all authorized positions posted and does not conduct interviews via social media, or other third-party sites or chat services. If you are unsure about a posting or email you receive, please contact us at askhr@dendreon.com. If you believe you are a victim of fraud, please contact your local law enforcement.
501 to 1000 staff
Diamond V
Diamond V™ is the dedicated brand for ruminant solutions in Cargill’s Micronutrition & Health Solutions (MHS) business. For over 80 years, Diamond V™ has supported dairy and beef producers with advanced micronutrition solutions that help raise healthier, more resilient herds. Built on a legacy of postbiotic innovation, Diamond V™ combines scientific leadership, ruminant expertise, and on-farm support to deliver measurable impact across operations. Diamond V’s targeted micronutrition solutions support immune function, rumen health, and feed efficiency—helping herds perform better and farms grow stronger. Backed by global research and powered by the scale and insight of Cargill Micronutrition and Health Solutions, Diamond™ V serves producers in nearly 70 countries with real, practical, science-based support. Diamond V™ products are based on global research, and innovation, all focused on transforming micronutrition into macro impact for beef and dairy producers worldwide. Cargill Micronutrition and Health Solutions is a specialized business within the portfolio of Cargill Animal Nutrition & Health.
201 to 500 staff
Discovery Life Sciences
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation. Visit to learn more
501 to 1000 staff
Dnanexus
DNAnexus, the enterprise platform for precision health, is on a mission to accelerate the development, approval and delivery of personalized treatments. Building on 15 years of bioinformatics innovation and genomics expertise, DNAnexus provides the cloud platform that centralizes and enriches multimodal omics data, supports an extensive suite of informatics use cases, and allows secure collaboration across the care continuum. DNAnexus powers a connected ecosystem trusted by the world’s precision health leaders. This flexible ecosystem makes omics and real-world data accessible, actionable, and secure, while unlocking insights that improve patient lives. For more information, visit or follow @DNAnexus on social media.
201 to 500 staff
Egenesis
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
51 to 200 staff
Emergent Biosolutions
At Emergent, we develop, manufacture, and deliver protections against public health threats. For more than two decades, we’ve been at work defending people from things we hope will never happen — so that we’re prepared, just in case they ever do. Please note: It has come to our attention that there may be people posing as Emergent recruiters and hiring managers online, offering fraudulent opportunities to job seekers. Emergent will never ask for any financial commitment from a candidate as a pre-employment requirement. Learn more about recruitment fraud and how to protect yourself here: https://bit.ly/recruitment-fraud
501 to 1000 staff
Enanta Pharmaceuticals
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT, STAT6 and MRGPRX2 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)(glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations.
51 to 200 staff
Envirologix
For over 20 years, we have focused on developing innovative testing solutions for a variety of needs, including the rapid detection of GMO traits in seed, corn, soybeans, other crops and in-process foods, mycotoxins in grain and foodborne pathogens as well as environmental applications. We partner with customers across the agricultural supply chain, from leading life science companies working on new technologies to small businesses interested in participating in the non-GMO project. We take pride in delivering point-of-need test results, helping our global customers make informed operational decisions daily.
51 to 200 staff
Evotec
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
5001 to 10000 staff
Fate Therapeutics Inc
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit
51 to 200 staff
Flagship Pioneering
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.
501 to 1000 staff
Formulatrix
FORMULATRIX® supplies innovative software and robotic automation solutions to the life science industry including the leading pharmaceutical companies and academic research institutions around the world. We collaborate with researchers to simplify scientific workflows such as sample preparation and analysis by designing solutions without boundaries and bringing novel cutting-edge technology into the laboratory. We are committed to researchers, their labs, and to the scientific discoveries that will improve the lives of generations to come.
1001 to 5000 staff
Fulgent Genetics
Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike- Our Products & Services - Fulgent Genetics Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver Fulgent is a CLIA-certified and CAP-accredited NASDAQ: FLGT
501 to 1000 staff
Genencor
Genencor is a world leader in industrial biotechnology and a pioneer in enzyme innovation. In more than 40 countries, Genencor’s 1,500 employees develop and market innovative enzymes and bio-based solutions to improve performance and reduce environmental impact in a wide range of industries, from laundry detergents to transportation fuels. In collaboration with our customers, technology leaders and other stakeholders, Genencor’s cutting-edge biotech platform provides competitive and sustainable solutions to the world, positioning Genencor as a key player in the emerging bio-based economy. In May 2011, DuPont acquired a majority stake in Danisco A/S, which includes its Genencor division. Genencor enzymes and enzyme production will now operate within DuPont Industrial Biosciences.
1001 to 5000 staff
Genomenon, Inc
Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company’s solutions include software, data, and services. Genomenon offers advanced genomic software solutions designed to streamline and enhance genetic research and clinical decision-making. Our flagship product, the Mastermind® Genomic Intelligence Platform, provides comprehensive genomic data integration and analysis, offering researchers and clinicians a powerful tool to interpret genetic variants and their clinical relevance. Complementing this is the Cancer Knowledgebase (CKB), which focuses specifically on the landscape of somatic mutations, offering curated, actionable insights to support oncology research and personalized cancer treatment. Together, these platforms aim to accelerate discoveries and improve patient outcomes through sophisticated data analysis and knowledge integration.
51 to 200 staff
Genscript
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,500 employees and has served more than customers across over 100 countries and regions.
5001 to 10000 staff
Geron Corporation
Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients. To learn more, visit Geron’s Community Guidelines:
201 to 500 staff
Gilson
Gilson provides high quality, dependable solutions for today's demanding liquid chromatography, solid phase extraction, liquid handling and gel permeation chromatography clean-up requirements. From the legendary PIPETMAN® products to a full range of system solutions, Gilson is the element of purification for your laboratory. Gilson has worldwide sales and service supporting the pharmaceutical, biotech, environmental, clinical, food & beverage and forensic markets. Our primary focus is on purifying samples via preparative HPLC, automated SPE or through GPC clean-up. Gilson focuses on early drug discovery and development with our preparative HPLC systems. Gilson's automated SPE systems and GPC clean-up systems support environmental, food & beverage, clinical and forensic markets performing a wide variety of clean-up applications. Headquartered in Middleton, Wisconsin, Gilson's innovative products will revolutionize the lab; providing the durability, flexibility, modularity and ease-of-use the industry has come to expect from Gilson. Gilson is an equal employment opportunity employer functioning under an affirmative action plan.
501 to 1000 staff
Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. We sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including GE Healthcare, Thermo Fisher Scientific Inc, and VWR. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, and Spain and sales facilities in France and Canada.
501 to 1000 staff
Highres Biosolutions
HighRes Biosolutions is the leading global laboratory automation company. Our products and people empower scientists with whole automated laboratory workflows, thus creating data factories that connect instrumentation with informatics around the world.
201 to 500 staff
Horizon
Horizon Therapeutics is now part of Amgen. The Horizon LinkedIn page is no longer active or monitored.
1001 to 5000 staff
Iddi
IDDI is a therapy-focused expert regulatory statistics, clinical data services and high-level strategic consulting contract research organization committed to increasing efficiency and mitigating risks throughout the drug development process. For over 30 years, we have provided agile clinical trial services for pharmaceutical, biotechnology, and medical device/diagnostic companies to ensure their clinical data is ready for submission. With a deep expertise in advanced biostatistics and study design, we also offer regulatory, statistical and clinical consultancy, comprehensive data management services and integrated RTSM-EDC for the successful execution of your clinical development program even with complex settings. IDDI is Passion, Science, and Experience to ensure your data is ready for submission!
51 to 200 staff
Ideaya Biosciences
IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.
51 to 200 staff
Igem Competition
The world’s biggest synthetic biology competition is pioneering and driving the growth of the field. Each year, it trains the next generation of leaders by giving multidisciplinary student teams the incentive, tools, training and platform to design, build, test, and present projects tackling the world’s most pressing challenges - while competing on the global stage.
10001+ staff
Igm Biosciences, Inc
About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).
51 to 200 staff
Immunitybio, Inc
ImmunityBio, Inc.(formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases."At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease."-Dr. Patrick Soon-Shiong, Executive Chairman
501 to 1000 staff
Immunologix Laboratories
Immunologix Laboratories is a unique scientific partner, offering GLP and GCP compliant laboratory capabilities focused on ligand binding-based bioanalysis coupled with expert scientific consultation from our Translational Sciences team. Our laboratory specializes in Immunogenicity, Neutralizing Antibody (cell-based and ligand binding based), PK, and Biomarker assays in support of preclinical and clinical studies. Translational Sciences provides dedicated scientific resources to advise, develop and implement scientific strategies and practical solutions for innovator development programs. Our fully customizable approach includes delivering stage-appropriate biomarker & bioanalytical strategies, assay development and validation, study data interpretation, and support for regulatory interactions and filings. Our exceptional scientific experts work together as an integrated team ensuring that our client’s projects receive full benefit of the breadth and depth of experience gained over many decades within both contract laboratory and drug development organizations. The integration of Translational Sciences with the laboratory is unique within our industry and this confluence of expertise enables our team to deliver valuable scientific insights that accelerate decision making and the course of drug development. Please contact us at info@immunologixlabs.com
51 to 200 staff
Immunotek Bio Centers, Llc
ImmunoTek Bio Centers is a biotech company committed to safely collecting high-quality blood plasma and supplying growth through new center development. At ImmunoTek, our donors make an impact with every life-changing donation they make and are an essential ingredient in providing lifesaving therapies to those patients who desperately need them. All ImmunoTek centers are FDA-regulated and follow strict industry standards and guidelines. Each center is staffed with a highly-trained and friendly team dedicated to procuring quality blood plasma. Our teammates are at the heart of everything we do at ImmunoTek and are devoted to serving our donors at every step of their journey. With nearly 100 years of combined experience in the blood, plasma, and biopharma industries, our leadership team provides the guidance needed for the success of our donors and teammates. ImmunoTek’s other specialty is constructing, opening, FDA/EU licensing, and managing multiple plasma collection centers and plasma supply contracts to meet ongoing demand in the plasma proteins therapeutics market in partnership with well-known pharmaceutical companies.
501 to 1000 staff
Inari
Inari is the SEEDesign™ company, using new breeding technology to push the boundaries of what is possible by designing nature-positive seeds for a more sustainable food system. A combination of AI-enabled predictive design and a cutting-edge multiplex gene editing toolbox enables Inari to unlock the full potential of seed and advance critical solutions with broad applications for growing more food with fewer resources – providing real benefits to farmers, our planet and the global population.
201 to 500 staff
Inseption Group
inSeption is a home for clients and professionals who have been stifled by mainstream, high-volume, commoditized outsourcing models. As a result, our connections form a framework that outperforms and outshines other providers.
201 to 500 staff
Insitro
insitro is the AI therapeutics company built on causal biology. By generating an integrated, multimodal corpus of human and cellular data and analyzing it with machine learning, insitro's platform aims to reveal how disease begins, progresses, and can be resolved. The company applies this approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience. insitro was founded by Daphne Koller and operates through a bilingual culture – cross-functional collaboration where machine learning scientists, discovery biologists, and drug hunters work as a single integrated unit. The company established partnerships with Bristol Myers Squibb, Eli Lilly, and Gilead, and is backed by world-class investors. insitro brings together expertise across computational biology, human genetics, bioengineering, automation, and drug discovery to help bring effective medicines to patients faster. Join us in transforming drug discovery and development!
201 to 500 staff
Invivogen
At InvivoGen, we strive to provide life scientists worldwide with innovative, high quality and reliable reagents. As specialists in cell culture engineering and innate immunity, we are passionate about designing, developing, and bringing to market new tools and services for cutting-edge research. At our three regional headquarters — in Toulouse (France), San Diego (USA) and Hong Kong (China) — and through our dedicated multilingual customer support staff, we can provide researchers around the globe with the reagents and product information that they need to make the scientific breakthroughs of tomorrow. InvivoGen is a privately held company founded by university researchers in 1977 in Toulouse, France. Since then, we have gradually expanded with the opening of InvivoGen San Diego, in 1997, and InvivoGen Hong Kong, in 2014. Our unparalleled skills in microbial fermentation enable us to produce a wide range of bioactive molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest available collection of pattern recognition receptor agonists, from various micro-organisms. Over 25% of InvivoGen’s employees hold a PhD in biology or chemistry. Through specialized R&D teams, they work together seamlessly to design, produce and validate novel plasmids, cell lines, vaccine adjuvants and synthetic ligands for research in areas as diverse as gene therapy, molecular immunology and vaccination. Moreover, based on our first-hand knowledge of innate immune receptor signaling pathways, we have devised an ever-expanding collection of reporter cell lines, including cytokine reporter cells and knockout (KO) cell lines for high-priority innate immune targets. Scientists depend on InvivoGen for quality, consistency and reliability. Whatever research challenges you are facing, count on InvivoGen to provide you with the tools and solutions that you need.
51 to 200 staff
Iovance Biotherapeutics, Inc
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings
501 to 1000 staff
Karius
Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.
51 to 200 staff
Kaycha Labs
A forefront provider of cannabis testing technologies and methodologies nationwide, our laboratories offer both regulatory and research & development (R&D) testing services in Arizona, Colorado, Florida, Massachusetts, North Carolina, Nevada, and New York. Kaycha’s network of accredited labs is a recognized for precision and speed, delivering results within 48 hours with sample automation and technology innovation. Kaycha labs implements over 500 procedures and methods to test Cannabis products using state-of-the-art equipment. These procedures and methods comply with standards set by the United States Food and Drug Administration (FDA), International Standards Organization (ISO), United States Department of Agriculture’s (USDA) Food Safety and Inspection Services, and Association of Analytical Communities (AOAC).
201 to 500 staff
Kbi Biopharma
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 500+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. KBI is proud to be a JSR Life Sciences Company.
1001 to 5000 staff
Kura Oncology, Inc
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at
51 to 200 staff
Labconco Corporation
Serving the scientific community since 1925, Labconco Corporation manufactures laboratory equipment, specializing in ventilation products such as chemical fume hoods and blowers, ductless fume enclosures, balance enclosures, HEPA-filtered biological safety cabinets (BSCs), clean benches, glove boxes, and laboratory animal research enclosures. Other product lines include glassware washers, forensic enclosures, centrifugal concentrators, lyophilizers, evaporators, and water purification systems. Custom designed products are also available. Protecting your laboratory environment is the foundation of Labconco's product development efforts, and every Labconco product is designed with safety in mind. Its products' performance meets or exceeds industry standards including ANSI/ASHRAE 110-1995, NSF Standard 49 and UL 61010-1. Labconco employs more than 200 associates, every one taking pride in providing outstanding customer service. Labconco is ISO 9001:2008 certified, one measure of its commitment to quality and consistency in design and manufacturing. Through a worldwide network of distributors, Labconco serves a variety of laboratory customers around the globe, including universities, research centers, hospitals and government agencies.
201 to 500 staff
Lifecell, An Acelity Company
LifeCell is now an Acelity company! Acelity is a global market leader in advanced wound therapeutics and regenerative medicine, offering innovative solutions from the hospital to home that improve the lives of patients in more than 80 countries. Our mission is to change the practice of medicine with solutions that speed healing, create economic value and improve patients’ lives. We are the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair, and the market leader in collagen dressings. Acelity is headquartered in San Antonio, Texas, with more than 5,800 employees around the globe. LifeCell is focused on the development and commercialization of regenerative and reconstructive acellular tissue matrices for use in general and reconstructive surgical procedures to repair soft tissue defects, as well as autologous fat grafting solutions. The LifeCell portfolio began with ALLODERM™ Regenerative Tissue Matrix, which launched in 1994, and expanded with the launch of STRATTICE™ Reconstructive Tissue Matrix in 2008, the same year that Kinetic Concepts, Inc.(KCI) acquired LifeCell. In 2012, LifeCell further expanded its portfolio with the launch of ALLODERM™ Ready to Use. In June 2013, LifeCell introduced the REVOLVE™ System to offer fast and efficient fat transfer processing for use in a range of aesthetic and reconstructive procedures. In 2014, KCI's parent company announced that KCI, LifeCell and Systagenix would operate under one global medical technology brand known as Acelity.
5001 to 10000 staff
Macrogen Inc
Established in 1997, Macrogen is a global digital healthcare company committed to enhancing the well-being of humanity through a healthcare platform and personal genome sequencing services. With the goal of providing every individual with a $100 "Genetic Blueprint" for a long and healthy life, Macrogen offers comprehensive genomic solutions that include DNA/RNA sequencing, personal genetic testing, microbiome analysis, single-cell sequencing, proteomics, cancer gene panels for clinical diagnosis, and even animal genetic testing. We have served over clients across 153 countries, adapting to the era of personalized medicine by focusing on disease prediction, prevention, tailored drug therapies, and new-drug development.
201 to 500 staff
Maravai Lifesciences
Maravai brands set the standard in nucleic acid products and services, enzyme development, and biologics safety testing. From producing revolutionary mRNA technologies that drive infectious disease vaccines, cancer vaccines, and other cell and gene therapies to delivering gold-standard bioprocess impurity detection solutions, Maravai is helping life sciences companies overcome their biggest development and manufacturing challenges to streamline and scale from research through clinical trials to commercialization. For over 35 years, Maravai’s brands have served as proven catalysts for innovative, lifesaving technology for humanity. Across our portfolio of brands, we hold numerous patents and offer more than 1,500 innovative products and services, including CleanCap® technology, CleanAmp® hot start PCR, Antibody Affinity Extraction™, EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV®, Sterling™, Glen Pak™, Glen Gel-Pak™. Each of our brands are ISO-9001:2015 certified and have earned hundreds of thousands of citations in peer-reviewed scientific publications.
501 to 1000 staff
